AUROPHARMA vs LINCOLN: Stock Comparison
AUROBINDO PHARMA is the larger company by market capitalisation. LINCOLN PHARMA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AUROPHARMA leads 3; LINCOLN leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AUROPHARMA | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AUROPHARMA | LINCOLN |
|---|---|---|
| Live Price | ₹1,610.9 | ₹510.85 |
| Day Change | 2.03% | -0.72% |
| Volume | 11.16 L | 61,149 |
| 52-Week High | ₹1,740 | ₹770 |
| 52-Week Low | ₹1,080.1 | ₹440 |
| Distance from 52W High | -7.42% | -33.66% |
Valuation
| Metric | AUROPHARMA | LINCOLN |
|---|---|---|
| Market Cap | ₹93,556 Cr | ₹1,023 Cr |
| P/E Ratio | 25.37x | 10.61x |
| P/B Ratio | 2.49x | 1.35x |
| EPS | ₹64 | ₹18.09 |
| Book Value | ₹652.39 | ₹378.25 |
| Dividend Yield | 0% | 0.35% |
Growth
| Metric | AUROPHARMA | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | 5.6% | 11.4% |
| EPS Growth (TTM YoY) | 1.9% | 0.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | AUROPHARMA | LINCOLN |
|---|---|---|
| ROE | 10.63% | 11.6% |
| ROCE | 9.64% | 10.97% |
| Net Margin | 10.62% | 13.1% |
| Operating Margin | 30.23% | 17.38% |
| Debt to Equity | 0.18x | 0.01x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | AUROPHARMA | LINCOLN |
|---|---|---|
| Promoter Holding | 48.8%▼ 0.01 pp | 49.78% |
| FII Holding | 17.41%▲ 1.03 pp | 4.6%▼ 0.59 pp |
| DII Holding | 24.42%▼ 0.68 pp | 0.27%▼ 0.82 pp |
| Public Holding | 6.29%▼ 0.35 pp | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AUROBINDO PHARMA and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.